ERBB2 and breast carcinoma: The monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib are currently clinical therapies targeting HER2 65, 66, however, adaptive resistance to anti‐HER2 therapy also occurrs in HER2‐positive breast cancer.